JP MORGAN/CALL/ELI LILLY & CO/1340/0.01/20.06.25 | Market Closed - Börse Stuttgart 01:06:25 31/05/2024 pm IST | ||
| 0.17 EUR | +6.25% |
|
| Current month | +54.55% | ||
| 1 month | +54.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.17 | +6.25% |
| 30/24/30 | 0.16 | +6.67% |
| 29/24/29 | 0.15 | -6.25% |
| 28/24/28 | 0.16 | -.--% |
| 27/24/27 | 0.16 | -.--% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 01:06 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK6Y0V |
| ISIN | DE000JK6Y0V6 |
| Date issued | 09/04/2024 |
| Strike | 1,340 $ |
| Maturity | 20/06/2025 (385 Days) |
| Parity | 100 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.17 € |
|---|---|
| Lowest since issue | 0.083 € |
| Spread | 0.03 € |
| Spread % | 17.65% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
- Stock Market
- Warrants
- Warrant
